FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors
The FDA approved Lantheus’ BRAVNETSA for neuroendocrine tumors. The decision gives Lantheus a newly cleared oncology product, with commercial uptake and revenue contribution now the next measurable milestones.
STOCK PHOTO · LEE STARRYThe story
The U.S. Food and Drug Administration approved Lantheus’ BRAVNETSA for the treatment of neuroendocrine tumors, according to the Sept. 22 report. The approval clears the product for commercialization in that tumor segment and adds an oncology therapy to Lantheus’ portfolio.
Lantheus reported $1.5B in revenue for the fiscal year ended Dec. 31, 2025, up 0.5% year over year. Its reported gross margin was 61.1%, net margin was 15.2% and diluted EPS was $3.41 for that period.
The immediate commercial connection is Lantheus: BRAVNETSA can now generate sales through prescribing, distribution and treatment use in neuroendocrine tumors. The approval also places the product within the company’s existing healthcare business, but the size and timing of any contribution are not established by the approval itself.
The key uncertainty is adoption. The regulatory decision establishes clearance, while future results will depend on launch execution, physician uptake, reimbursement and the product’s contribution relative to Lantheus’ existing revenue base.
Investors will have to track launch timing, early sales and the company’s next financial update for evidence of commercial scale. The next relevant milestones are Lantheus’ disclosures on commercialization and the company’s upcoming quarterly results.
Our read · Tue, Sep 22
FDA approval clears Lantheus (LNTH) to market BRAVNETSA for neuroendocrine tumors.
Why. The approval creates a new commercial product opportunity, but the financial payoff depends on launch execution and physician adoption rather than the regulatory decision alone. Lantheus’ $1.5B of 2025 revenue and 15.2% net margin provide an established base, while the next quarterly results should show whether BRAVNETSA is becoming material.
Both cases
What could change this view: Limited uptake, reimbursement friction or a delayed launch could leave BRAVNETSA immaterial to revenue despite the approval.
Who reported it · 1
Keep reading
Latest on the Wire
Intesa Sanpaolo launches €34.5bn cash-and-share offer for Monte dei PaschiIran war sees tanker hit near Hormuz as Saudi Arabia intercepts Houthi missilesNvidia tumbles as US tech stocks enter bear market on AI spending fearsTrump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testContinue on the Wire →Latest on the Wire
Greer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultAnthropic debut fails to halt technology-led slide in US stocksContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by Investing.com, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →